Alcobra Ltd. (NASDAQ:ADHD) shares were up 14.4% during mid-day trading on Wednesday . The company traded as high as $5.23 and last traded at $5.00, with a volume of 193,163 shares trading hands. The stock had previously closed at $4.37.

A number of research analysts recently issued reports on ADHD shares. Barclays PLC started coverage on shares of Alcobra in a research note on Monday. They issued an “equal weight” rating and a $8.00 price objective on the stock. Zacks Investment Research cut shares of Alcobra from a “hold” rating to a “sell” rating in a research note on Monday, July 18th. Canaccord Genuity started coverage on shares of Alcobra in a research note on Tuesday, June 7th. They issued a “buy” rating on the stock. Roth Capital reissued a “buy” rating and issued a $12.00 price objective on shares of Alcobra in a research note on Tuesday, June 21st. Finally, Cantor Fitzgerald started coverage on shares of Alcobra in a research note on Tuesday, June 7th. They issued a “buy” rating and a $16.00 price objective on the stock. Three equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $10.25.

The firm’s 50 day moving average price is $4.37 and its 200 day moving average price is $4.57. The company’s market cap is $137.81 million.

Alcobra (NASDAQ:ADHD) last posted its earnings results on Monday, May 16th. The company reported ($0.18) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.22) by $0.04. Equities research analysts expect that Alcobra Ltd. will post ($0.97) EPS for the current fiscal year.

Alcobra Ltd is an Israel-based Biopharmaceutical company. It focuses on the development and commercialization of a proprietary drug, MG01CI, to treat Attention Deficit Hyperactivity Disorder (ADHD), a common and morbid neuropsychiatric condition in children and adults. Adult ADHD is associated with increased health risks and healthcare costs, higher divorce rates, lower levels of socioeconomic attainment, lower academic achievement, unemployment and work place deficits, increased risks for motor vehicle accidents, greater likelihood of additional psychiatric disorders, increased criminal activity and incarceration, and higher rates of substance use and abuse.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.